Lupin News and Updates

Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Lupin from all sources in a single place.

Load latest

Lupin Ltd.

06 Aug 2025

2113.10

1.08%

to see Rapid results content

Lupin Ltd.

05 Aug 2025

2113.10

1.08%

Lupin Q1 Results: Net Profit Jumps 52% To Rs 1,221 Crore

NDTV Profit

Sales rose to Rs 6,164 crore in the first quarter as against Rs 5,514 crore in the year-ago period, Lupin Ltd said in a statement.

Lupin Ltd. is trading above all available SMAs

Lupin Q1 results: Net profit jumps 52% to 1,221 cr on strong sales in US

Business Standard | 05 Aug 2025

Lupin Ltd.

24 Jul 2025

2113.10

1.08%

Lupin gets USFDA nod for generic diabetes drugs

Business Line

The company received approval from the USFDA for its abbreviated new drug applications for Liraglutide Injection single-patient-use prefilled pens and glucagon for injection vials, the drug maker said in a statement

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

17 Jul 2025, 10:36AM

2113.10

1.08%

Lupin share price increases on rolling out eye medication; details here

Business Standard

Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market.

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

10 Jul 2025

2113.10

1.08%

Lupin, Zentiva Group ink agreement to commercialise biosimilar Certolizumab Pegol

Business Line

Both parties will invest in the development of the new biosimilar

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

09 Jul 2025

2113.10

1.08%

Lupin share pops 2% on licencing and supply agreement with Zentiva; details

Business Standard

Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for the commercialisation of its biosimilar Certolizumab Pegol.

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

04 Jul 2025

2113.10

1.08%

Lupin launches nasal spray in US, part of 200-drug pipeline by FY30

Business Standard

The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin launches generic Ipratropium Bromide nasal spray in US market

Business Line | 04 Jul 2025

Lupin Ltd.

03 Jul 2025

2113.10

1.08%

Lupin (BUY): Lupin carves out Consumer Healthcare business

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's OTC carve-out won't significantly impact financials, but aims to double OTC sales by sharpening focus

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

01 Jul 2025

2113.10

1.08%

Lupin carves out consumer healthcare biz into wholly owned subsidiary

Business Standard

The carve-out will be effective from 1 July 2025, according to the company's regulatory filing on the exchanges.

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Drugmaker Lupin creates a separate entity for its consumer healthcare business

Business Line | 01 Jul 2025 1 more

Lupin Ltd.

26 Jun 2025

2113.10

1.08%

Lupin launches generic chronic constipation treatment drug in US

Business Line

The company has launched Prucalopride tablets of strengths 1 mg and 2 mg in the US, following the recent approval of its abbreviated new drug application (ANDA) from the USFDA

Lupin Ltd. is trading above all available SMAs

Is Lupin Ltd. worth buying?

933 Votes:

Buy 72.78%

Sell 17.58%

Hold 9.65%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf